Premium
Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen‐reduced platelets
Author(s) -
Bahar Burak,
Schulz Wade L.,
Gokhale Amit,
Spencer Bryan R.,
Gehrie Eric A.,
Snyder Edward L.
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16187
Subject(s) - platelet , medicine , platelet transfusion , sepsis , blood transfusion , gastroenterology , surgery , anesthesia , immunology
Summary Pathogen‐reduced (PR) platelets are routinely used in many countries. Some studies reported changes in platelet and red blood cell (RBC) transfusion requirements in patients who received PR platelets when compared to conventional (CONV) platelets. Over a 28‐month period we retrospectively analysed platelet utilisation, RBC transfusion trends, and transfusion reaction rates data from all transfused adult patients transfused at the Yale‐New Haven Hospital, New Haven, CT, USA. We determined the number of RBC and platelet components administered between 2 and 24, 48, 72 or 96 h. A total of 3767 patients received 21 907 platelet components (CONV = 8912; PR = 12 995); 1,087 patients received only CONV platelets (1578 components) and 1,466 patients received only PR platelets (2604 components). The number of subsequently transfused platelet components was slightly higher following PR platelet components ( P < 0·05); however, fewer RBCs were transfused following PR platelet administration ( P < 0·05). The mean time‐to‐next platelet component transfusion was slightly shorter following PR platelet transfusion ( P = 0·002). The rate of non‐septic transfusion reactions did not differ (all P > 0·05). Septic transfusion reactions ( N = 5) were seen only after CONV platelet transfusions ( P = 0·011). These results provide evidence for comparable clinical efficacy of PR and CONV platelets. PR platelets eliminated septic transfusion reactions without increased risk of other types of transfusions with only slight increase in platelet utilisation.